Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL ...

AstraZeneca’s small molecule lowered levels of “bad” cholesterol by more than half in patients who had never received treatment for their condition, according to results from an early-stage trial. The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A once-daily oral PCSK9 inhibitor reduced LDL in ...

Panelists discuss how PCSK9 inhibitors remain underused due to access, cost, and adherence barriers.

PHILADELPHIA, PA—A novel, long-acting PCSK9 inhibitor that is injected just once every 3 months can reduce LDL-cholesterol levels by more than 50% compared with placebo in patients already taking ...

Please provide your email address to receive an email when new articles are posted on . An oral PCSK9 inhibitor lowered LDL cholesterol by up to 60% and improved other lipid parameters at 24 weeks.

A new study suggests that the cholesterol-regulating protein PCSK9 may serve as a sensitive early biomarker for autoimmune liver diseases.

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients' treatment significantly reduced the risk of major ...

Chronic kidney disease is a growing problem globally. A new study from Aarhus University shows that a protein known for treating heart diseases also affects a mechanism in the kidney that reabsorbs ...